| Cholangiocarcinoma
Tibsovo vs Pemazyre
Side-by-side clinical, coverage, and cost comparison for cholangiocarcinoma.Deep comparison between: Tibsovo vs Pemazyre with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPemazyre has a higher rate of injection site reactions vs Tibsovo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Pemazyre but not Tibsovo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tibsovo
Pemazyre
At A Glance
Oral
Daily
IDH1 inhibitor
Oral
Once daily
FGFR1-3 inhibitor
Indications
- Leukemia, Myelocytic, Acute
- MYELODYSPLASTIC SYNDROME
- Cholangiocarcinoma
- Cholangiocarcinoma
- Myeloid/lymphoid neoplasm
Dosing
Leukemia, Myelocytic, Acute 500 mg orally once daily; newly diagnosed: in combination with azacitidine 75 mg/m2 SC or IV on Days 1-7 of each 28-day cycle, or as monotherapy, for minimum 6 months; relapsed/refractory: monotherapy until disease progression or unacceptable toxicity.
MYELODYSPLASTIC SYNDROME 500 mg orally once daily as monotherapy until disease progression or unacceptable toxicity; continue for minimum 6 months.
Cholangiocarcinoma 500 mg orally once daily until disease progression or unacceptable toxicity.
Cholangiocarcinoma 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy, in 21-day cycles; continue until disease progression or unacceptable toxicity.
Myeloid/lymphoid neoplasm 13.5 mg orally once daily on a continuous basis; continue until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) leukocytes decreased, diarrhea, hemoglobin decreased, platelets decreased, glucose increased, fatigue, alkaline phosphatase increased, edema, potassium decreased, nausea, vomiting, phosphatase decreased, decreased appetite, sodium decreased, leukocytosis, magnesium decreased, aspartate aminotransferase increased, arthralgia, dyspnea, uric acid increased, abdominal pain, creatinine increased, mucositis, rash, electrocardiogram QT prolonged, differentiation syndrome, calcium decreased, neutrophils decreased, myalgia
Serious differentiation syndrome, electrocardiogram QT prolonged, leukocytosis, Guillain-Barre syndrome
Most common (>=15%) Hyperphosphatemia, alopecia, nail toxicity, diarrhea, fatigue, nausea, stomatitis, dry eye, dry mouth, constipation, decreased appetite, dysgeusia, arthralgia, abdominal pain, hypophosphatemia, vomiting, back pain, dry skin, edema peripheral, rash, anemia, epistaxis
Serious Abdominal pain, pyrexia, cholangitis, pleural effusion, acute kidney injury, cholangitis infective, failure to thrive, hypercalcemia, hyponatremia, small intestinal obstruction, urinary tract infection
Pharmacology
Ivosidenib is a small molecule inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme that reduces 2-hydroxyglutarate (2-HG) levels and induces myeloid differentiation in IDH1-mutated AML; in IDH1-mutated cholangiocarcinoma, it also reduces 2-HG levels in tumor tissue.
Pemigatinib is a selective small molecule inhibitor of fibroblast growth factor receptors 1, 2, and 3 (FGFR1-3) that blocks receptor phosphorylation and downstream signaling, inhibiting proliferation of cancer cells harboring activating FGFR amplifications, fusions, or rearrangements.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tibsovo
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (4/12) · Qty limit (12/12)
Pemazyre
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Tibsovo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Pemazyre
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Tibsovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Pemazyre
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tibsovo.
Cost estimate not availableAssistance Fund: Biliary Tract Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TibsovoView full Tibsovo profile
PemazyreView full Pemazyre profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.